南风轻轻，中药飘香。 2024年12月19日，习近平总书记在澳门科技大学考察时指出："中医药是中华文明的瑰宝，传承创新发 展中医药是件大事。要把这一祖先留给我们的宝贵财富继承好、发展好、利用好，推动中医药走向世 界。" 2018年10月22日，习近平总书记考察珠海横琴新区粤澳合作中医药科技产业园时强调："中医药学是中 华文明的瑰宝。要深入发掘中医药宝库中的精华，推进产学研一体化，推进中医药产业化、现代化，让 中医药走向世界。" 总书记两次考察，格外关注中医药。"十五五"规划建议提出："推进中医药传承创新，促进中西医结 合。"中医药振兴发展迎来天时、地利、人和的有利时机。 近年来，广东省出台一系列促进中医药传承创新发展的重大举措，全面推进国家中医药综合改革示范区 建设，打造粤港澳大湾区中医药高地，助力中医药扬帆出海，续写岐黄之术的新时代篇章。 一株小草改变世界，一纸经方传承千载，一缕药香穿越古今，一根银针贯通中西。古老的中医药薪火相 传、历久弥新，成为一张亮眼的"中国名片"。 从一只蜂看中医特色 冰箱里堆满"调料包"，厨房就是"中药房"，一年四季都在吃药膳、煲靓汤、喝凉茶。在广东，几乎人人 都能说出一两个养生药 ...

（文章来源：证券日报） 证券日报网讯 2月25日，吉林敖东在互动平台回答投资者提问时表示，公司围绕医药主业，积极借鉴行 业优秀经验，推动医药生产、制造的智能化升级与数字化发展，助力中医药现代化进程。公司以开放姿 态积极对接具备先进经营理念、技术优势与产业协同的优质合作方，不断优化经营模式，提升运营效率 与核心竞争力。目前公司正积极推进医药营销改革，通过整合各营销板块、组建营销事业群，优化管理 体系、形成发展合力、统一资源，实现营销突破，助力公司高质量发展。 ...

央视网消息：记者从1月28日举行的全国中医药局长会议上了解到，刚刚过去的一年，中医药发展规划和中医药振兴发展重大工程各项任 务落地见效。 国家中医药管理局规划财务司司长 刘群峰：2026年我们将认真编制实施好中医药领域的"十五五"规划，科学谋划一批引领性的重大工程 和项目，更好发挥中医药特色与优势。围绕生育健康、妇女儿童青少年健康，优化中医药服务供给，大力推进基层适宜技术推广和培训，持续 实施中医康复服务能力提升工程，在公立医院高质量发展和县域医共体建设等工作中，强化中西结合服务导向，加快推进中药现代化产业化， 全方位保障人民群众健康。 2025年，我国中医药传承创新发展取得了新成效。增补90个神志病、儿科、妇科等领域国家中医优势专科。聚焦重大疑难疾病，开展了 212个中西医临床协作项目。"中医药现代化"重点专项立项57个，支持开展儿童中药研发，中医药防治免疫、代谢等重大疑难疾病等科学研 究。截至2025年12月底，中医药研究领域已布局13个全国重点实验室、31家国家中医药传承创新中心。 ...

Group 1 - The core viewpoint of the article emphasizes the development and promotion of traditional Chinese medicine (TCM) through various initiatives and projects aimed at enhancing its modern application and international outreach [1][2][3]. Group 2 - The article mentions the selection of 15 innovative development demonstration projects focusing on major clinical collaboration initiatives [3]. - It highlights the establishment of 57 suitable directories to enhance the service system of TCM, aiming to integrate TCM advantages into healthcare [2]. - The article discusses the promotion of 20 types of characteristic medicines and the implementation of 11 innovative applications in the field of TCM [8][9].

Core Viewpoint - Zhejiang Zhenyuan, a century-old brand, combines traditional Chinese medicine culture with modern innovation to achieve high-quality development and explore new growth areas in synthetic biology [1][4]. Group 1: Company Background and Heritage - Zhejiang Zhenyuan originated from a small pharmacy in 1752 and has evolved into a modern enterprise integrating pharmaceutical manufacturing, commerce, and health services [1]. - The company is deeply rooted in the rich cultural heritage of the Yue region, which has significantly influenced its development and the establishment of the "Yue Medicine" system [2]. - Zhenyuan Tang, the company's predecessor, has maintained its commitment to authenticity and quality for over 270 years, making it a representative of Yue medicine culture [2][3]. Group 2: Business Evolution and Achievements - After the reform and opening-up, Zhenyuan Tang was among the first to complete a shareholding reform and became one of the first "Chinese Time-honored Brands" in 1996 [3]. - The company was listed on the Shenzhen Stock Exchange in 1997, marking it as the first listed company recommended by the National Administration of Traditional Chinese Medicine [3]. - Zhenyuan has expanded its business into various sectors, including pharmaceutical manufacturing, retail, and health services, establishing a complete industrial chain [3]. Group 3: Innovation and New Ventures - In 2022, Zhejiang Zhenyuan entered the synthetic biology sector by establishing a wholly-owned subsidiary and investing over 1.1 billion yuan in an industrialization project [4]. - The company has developed a diverse product system focusing on amino acids and has established partnerships with top research institutions for collaborative innovation [4][5]. - Zhenyuan has achieved significant breakthroughs, including the establishment of the first large-scale industrialization facility for histidine synthesis in China [5]. Group 4: Modernization of Traditional Medicine - Zhejiang Zhenyuan is innovating traditional medicinal recipes into convenient products, such as the "Zhenyuan Yue Meal" series, making traditional health solutions more accessible [6]. - The company is actively involved in setting international standards for toxic herbal materials, aiming to integrate traditional Chinese medicine with global practices [6]. - Zhenyuan is exploring the development of health products that combine food and medicine, enhancing the daily integration of traditional medicine into consumers' lives [6]. Group 5: Future Outlook - The company aims to strengthen its pharmaceutical manufacturing while positioning synthetic biology as a core growth area [7]. - It plans to expand its retail operations and enhance the quality of pharmaceutical services, focusing on the refinement of traditional Chinese medicine and the development of health and wellness industries [7].

Core Viewpoint - The establishment of the Hong Kong government’s permanent Chinese medicine testing center marks a significant milestone in the development of traditional Chinese medicine (TCM) in Hong Kong, aiming to promote TCM globally and enhance its quality standards [1][6]. Group 1: Development of the Testing Center - The permanent building of the Chinese medicine testing center will be operational in phases starting December 2025, covering an area of 17,200 square meters [1]. - The center will feature a world-class herb specimen museum, housing over 3,500 herbal specimens, including rare and commonly used varieties donated by the mainland [2][3]. - The center aims to establish international standards and testing methods for Chinese medicine, having already developed over 340 reference standards for various herbal materials [4]. Group 2: Technological Advancements - The center has implemented a "digital herb specimen museum," creating 3D images of herbal specimens to enhance traceability and detail [3]. - Advanced laboratories equipped with over 3,300 devices will support the development of widely applicable testing methods, significantly reducing costs and time for testing [4]. Group 3: International Collaboration and Outreach - The center will serve as a hub for international cooperation and training, enhancing exchanges in herbal testing technology with global institutions [6]. - Plans are in place to collect herbal specimens from Southeast Asia and collaborate with international research institutions to strengthen Hong Kong's position as a global trading hub for quality Chinese medicine [6].

柔和的灯光下，中药标本馆的一排排木色展柜琳琅满目，一株株药用植物标本栩栩如生；标本实验室 内，身着白大褂的科研人员操作着现代化的仪器设备，传统中药材的沟壑纹理在屏幕上清晰可见；神农 本草园里，约180种岭南特色药用植物争奇斗艳、欣欣向荣…… 香港中医药发展的旗舰机构、占地1.72万平方米的政府中药检测中心永久大楼自2025年12月起分阶段启 用，标志着香港中药发展迈向新的里程碑。日前，记者到访政府中药检测中心永久大楼，感受香港推动 中医药走向世界的决心与底气。 系统展示中药的完整生命周期 "这里存放了3500多份中药材标本，其中最珍贵的就在我身后这5个展柜，比如这株1.2米长的野生黄芪 和这株1.5米长的肉苁蓉。"在中药标本馆内，特区政府卫生署中医药规管办公室政府中药检测中心科学 主任（医务）王盛洲告诉记者，中药标本是中药科研检测和对比鉴别不可或缺的实物依据，标本馆存有 国家向香港赠送的超过300份常用及珍稀贵细中药材标本。 设立世界级的中药标本馆，是建设政府中药检测中心永久大楼的重要目标。中药标本馆及标本实验室负 责收集、鉴定、保存、展示和研究中药及其他草药标本。从平面到立体，从原植物、原药材到临床饮片 及 ...

在中医药现代化的时代浪潮下，传统中药工艺正借助科技力量实现迭代升级。近日，国家重点研发计划"中医药现代化"重点专项"12种中药发酵饮片关键 技术研究与产业化应用示范"项目启动会正式召开。作为该项目的核心参与企业，杭州市的桐君谷生物医药科技(浙江)有限公司(以下简称"桐君谷")凭借自 身技术与产业优势，助力中药发酵饮片产业突破发展瓶颈，加速现代化升级的步伐。 据悉，此次国家重点研发计划项目由河南中医药大学牵头统筹，汇聚了国内顶尖高校、科研院所及国内发酵中药龙头企业等多方优质资源，形成产学研用 深度融合的创新联合体。项目聚焦中药发酵饮片领域的核心技术瓶颈，以12种中药发酵饮片为研究对象，旨在突破关键工艺技术、构建科学质量控制体 系，最终实现产业化应用示范，助力中医药传承创新发展。 作为项目核心参与企业，桐君谷凭借深厚的产业积淀、领先的技术实力，成为推动项目落地见效的关键力量。据悉，桐君谷深耕中药发酵领域多年，不仅 自主研发了智慧发酵系统，成功培育12个发酵品种，更作为浙派发酵工艺的引领者，在中药发酵技术研发、产业化落地等方面积累了丰富经验。 在此次项目推进过程中，桐君谷将重点承担发酵中药智能装备研发、生产线集成与 ...

Core Viewpoint - Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. under Zhongheng Group's "Morning Bell" brand is set to be included in the 2025 China Consumer Brand List, marking a significant milestone in its brand development and recognition as a national quality consumer brand [1][2]. Group 1 - The 2025 China Consumer Brand List is the first national-level consumer brand evaluation led by the Ministry of Industry and Information Technology, aimed at promoting consumption upgrades and cultivating globally recognized brands [1]. - The "Morning Bell" brand, registered in 1986, is associated with the flagship product, Thrombolytic Injection (freeze-dried), which has received multiple awards, including the National Science and Technology Progress Award (Second Class) and the China Patent Excellence Award [1]. - The company emphasizes its development philosophy of "Creating Quality Chinese Medicine to Protect People's Health" and integrates traditional Chinese medicine wisdom with modern pharmaceutical technology [1]. Group 2 - Wuzhou Pharmaceutical is committed to increasing R&D investment through its national-level technology center and collaborative innovation platforms, focusing on modernizing and refining the "Morning Bell" brand products [2]. - The company aims to leverage its inclusion in the China Consumer Brand List to enhance brand development, accelerate innovation-driven growth, and expand its market presence [2].

Group 1 - The Ministry of Industry and Information Technology has announced the 2025 list of China's consumer brands, with Guangxi Wuzhou Pharmaceutical Group Co., Ltd.'s "Morning Bell" brand successfully selected, marking a significant milestone in the brand's development [2] - "Morning Bell" brand, registered in 1986, is associated with the flagship product, Thrombolytic Injection (lyophilized), which is well-regarded in the cardiovascular field due to its advanced freeze-drying technology and comprehensive quality control system [2][3] - The brand has achieved national market coverage across 31 provinces and cities, and has been included in the 2025 list of "China's 500 Most Valuable Brands," with a brand value assessment of 8.216 billion RMB, ranking 489th [3] Group 2 - The company emphasizes a development philosophy of "Creating Good Chinese Medicine for People's Health," focusing on a full industry chain quality control system and integrating traditional Chinese medicine wisdom with modern pharmaceutical technology [3] - The company has invested in research and development, leveraging a national-level technology center and collaborative innovation platforms to enhance the modernization and refinement of "Morning Bell" products, thereby maintaining market advantages [3] - Moving forward, the company aims to deepen brand development, accelerate innovation-driven growth, and expand its national market presence while upholding the essence of traditional medicine [3]